NTD Good Morning Full Broadcast (Oct. 25)

Danish pharma giant Novo Nordisk has asked the Food and Drug Administration (FDA) to stop compounding pharmacies from manufacturing versions of its weight-loss and diabetes drugs, claiming the main compound is too complex to replicate safely.In the Oct. 22 request, Novo Nordisk asked the FDA to include semaglutide on its Demonstrable Difficulties for Compounding (DDC) lists. Semaglutide is the act